Skip to main content

European Forum for Vaccine Vigilance
We Stand for Freedom of Choice In Vaccination For All Europeans

Measles and antibody-dependent enhancement

You might think that antibody-dependent enhancement is something that suddenly appeared during the covid period, but that is not true.

ADE has been known as a bad reaction to reinfection or vaccination. So if you have already been vaccinated with this new gene technology, there is a high possibility of ADE, an inadequate response to reinfection or a booster.

We share this new article by Helene Banoun (bio) that highlights history and mechanism of ADE with measles, dengue and coronaviruses.

It is worth a read and simple to understand: article

Here is the conclusion:


The inactivated measles vaccine has caused atypical measles, probably related to ADE, with proposed mechanisms involving the level and balance of certain types of antibodies induced by the vaccine. In rare cases of atypical measles (not always aggravated) reported following the current attenuated vaccine, the same mechanism has been proposed recently.

Measles seems to be more severe in the vaccine era and not only because of the displacement phenomenon (from infancy to adulthood), since in young adults without immunity the disease seemed less severe in the pre-vaccine era. This aggravation could be explained by the phenomenon of facilitation of infection by vaccine antibodies (ADE: antibody-dependent enhancement), whose level decreases with time and which would present a lesser affinity with wild circulating strains: the vaccine was conceived against a virus isolated in the 1960s. Wild viruses are still circulating and are antigenically distant from the vaccine virus dating from the 1960s: circulating wild-type measles virus strains may be partially resistant to antibodies induced by the live-attenuated vaccine.

During the massive vaccination campaign amid the 2019 measles outbreak in Samoa, the many infants and young child deaths could be due to ADE caused by insufficient levels of maternal antibodies facilitating infection with the live attenuated vaccine. So, facilitation could occur in infants because of the persistence of low-rate or low-affinity maternal antibodies and in young adults because of the decrease of titers and/or low affinity of vaccine antibodies.

The levels and specificity of antibodies present in persons with severe or atypical measles vaccinated with the attenuated vaccine should be explored and other types of vaccines may be considered.